UBS AM’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-33,590
| Closed | -$3.26M | – | 2937 |
|
|
2019
Q3 | $3.26M | Buy |
33,590
+3,266
| +11% | +$327K | ﹤0.01% | 1393 |
|
|
2019
Q2 | $3.1M | Buy |
30,324
+3,652
| +14% | +$394K | ﹤0.01% | 1394 |
|
|
2019
Q1 | $3.04M | Sell |
26,672
-141,333
| -84% | -$10.4M | ﹤0.01% | 1338 |
|
|
2018
Q4 | $6.58M | Sell |
168,005
-4,435
| -3% | -$192K | 0.01% | 991 |
|
|
2018
Q3 | $9.41M | Sell |
172,440
-7,057
| -4% | -$483K | 0.01% | 950 |
|
|
2018
Q2 | $14.9M | Buy |
179,497
+34,557
| +24% | +$2.67M | 0.01% | 850 |
|
|
2018
Q1 | $9.65M | Buy |
144,940
+959
| +0.7% | +$55.4K | 0.01% | 941 |
|
|
2017
Q4 | $7.4M | Buy |
143,981
+6,378
| +5% | +$458K | 0.01% | 991 |
|
|
2017
Q3 | $12.3M | Sell |
137,603
-37,460
| -21% | -$2.84M | 0.01% | 852 |
|
|
2017
Q2 | $10.5M | Sell |
175,063
-9,465
| -5% | -$529K | 0.01% | 894 |
|
|
2017
Q1 | $9.84M | Sell |
184,528
-508
| -0.3% | -$30.2K | 0.01% | 890 |
|
|
2016
Q4 | $9.23M | Buy |
185,036
+10,616
| +6% | +$569K | 0.01% | 881 |
|
|
2016
Q3 | $10.5M | Buy |
174,420
+26,909
| +18% | +$1.55M | 0.01% | 867 |
|
|
2016
Q2 | $7.54M | Sell |
147,511
-5,461
| -4% | -$233K | 0.01% | 933 |
|
|
2016
Q1 | $4.51M | Buy |
152,972
+10,472
| +7% | +$330K | 0.01% | 1049 |
|
|
2015
Q4 | $6.46M | Buy |
142,500
+2,200
| +2% | +$115K | 0.01% | 986 |
|
|
2015
Q3 | $5.86M | Buy |
+140,300
| New | +$7.32M | 0.01% | 1009 |
|
UBS AM's ONCE Position: Q4 2019 in Review
UBS AM sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 33,590 shares — an estimated $3.26M sold.
UBS AM first reported a position in ONCE in Q3 2015 and held it in 17 quarters. The position peaked at $14.9M in Q2 2018. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- UBS AM reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- UBS AM sold 33,590 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $3.26M.
- UBS AM first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2015 and held it in 17 quarters.
- UBS AM's Spark Therapeutics, Inc. Common Stock position peaked at $14.9M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on UBS AM's 13F filing for Q4 2019, filed 14 Feb 2020.